• Venture Lending
    • Ventures Overview
    • Ventures Portfolio
    • Ventures FAQs
  • Equipment Leasing
    • Lease Financing
    • Capital Markets
    • Equipment Types
    • Services
    • Clients
  • Properties
  • Investors
    • Institutional Investors
    • Retail Investors
  • Resources
    • Insights
    • News
  • Company
    • Our Team
    • Careers
    • ATEL Foundation
    • Contact

ViaCyte

Life Sciences, Venture Debt

Develops cell replacement therapies for diabetes. ViaCyte was acquired by Vertex Pharmaceuticals in 2022.

Skills

Posted on

December 17, 2024

← Twist Bioscience Xiacato →